S. Clarke

Oncology · Journal of Clinical Oncology · 2008–2023

A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom S. Clarke trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. McMillan (in Oncology)

Papers from S. Clarke's perspective

Ordered by how strongly the researchers S. Clarke trusts endorse each paper. Same corpus, a different order for every researcher.

  1. The hallmarks of cancer (RNA Biology)
  2. Hallmarks of cancer: the next generation. (Cell)
  3. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. (Bratislava Medical Journal)
  4. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study… (Journal of Clinical Oncology)
  5. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. (Journal of Clinical Oncology)
  6. Capecitabine as adjuvant treatment for stage III colon cancer. (New England Journal of Medicine)
  7. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. (Journal of Clinical Oncology)
  8. Neutrophil‐lymphocyte ratio as a prognostic factor in colorectal cancer (Journal of Surgical Oncology)
  9. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. (Future Oncology)
  10. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. (Journal of Clinical Oncology)

Their papers